- $7.29m
- $31.81m
- $2.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.07 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.19% | ||
| Return on Equity | -11.42% | ||
| Operating Margin | -933.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 3.53 | 2.91 | 3.11 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OSR Health, Inc., formerly OSR Holdings, Inc., is a healthcare holding company. Its platforms include immuno-oncology, regenerative biologics, noninvasive glucose monitoring and medical device technologies. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Its VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM. Its Darnatein platform is a synthetic biology platform employing AI to generate hybrid versions of endogenous proteins. Lead asset DRT-101 is engineered to function as a BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical needs and potential as a DMOAD. RMC is engaged in medical device distribution business that is also evolving into fourth-party logistics (4PL), offering bundled import licensing, regulatory, and logistics services.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- February 25th, 2020
- Public Since
- February 10th, 2023
- No. of Shareholders
- 75
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 35,118,692
- Address
- 10900 Ne 4Th Street, Suite 2300, BELLEVUE, 98004
- Web
- https://osr-health.com
- Phone
- +1 4256357700
- Auditors
- WithumSmith Brown PC
Latest News for OSRH
Upcoming Events for OSRH
Q3 2026 OSR Health Inc Earnings Release
Q4 2026 OSR Health Inc Earnings Release
Similar to OSRH
ABPRO Holdings
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adaptin Bio
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
FAQ
As of Today at 22:33 UTC, shares in OSR Health are trading at $0.21. This share price information is delayed by 15 minutes.
Shares in OSR Health last closed at $0.21 and the price had moved by -67.85% over the past 365 days. In terms of relative price strength the OSR Health share price has underperformed the S&P500 Index by -71.22% over the past year.
The overall consensus recommendation for OSR Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOSR Health does not currently pay a dividend.
OSR Health does not currently pay a dividend.
OSR Health does not currently pay a dividend.
To buy shares in OSR Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.21, shares in OSR Health had a market capitalisation of $7.29m.
Here are the trading details for OSR Health:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: OSRH
Based on an overall assessment of its quality, value and momentum OSR Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in OSR Health is $10.00. That is 4715.8% above the last closing price of $0.21.
Analysts covering OSR Health currently have a consensus Earnings Per Share (EPS) forecast of -$1.09 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OSR Health. Over the past six months, its share price has underperformed the S&P500 Index by -71.14%.
As of the last closing price of $0.21, shares in OSR Health were trading -51.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OSR Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on OSR Health's directors